Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

More Details about Hisun-Pfizer and Merck-Simcere JVs

publication date: May 20, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
In 2011, the world’s two largest drugmakers – Pfizer and Merck – each announced major China drug JVs with domestic China pharmas – Hisun in Pfizer’s case and Simcere for Merck. The arrangements were high-profile, and their aims went beyond drug distributorship, reaching into drug development. But details have been slow to emerge. A recent article in People’s Daily shed some light on these important JVs, which are now just getting under way. More details....

Stock Symbols: (NYSE: PFE) (NYSE: MRK) (SHA: 600267) (NYSE: SCR)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners